Overview

Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

Status:
Enrolling by invitation

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

This is a long-term follow-up to an earlier study, LA38-0411. Its purpose is to gather more information about the safety and efficacy of deferiprone in patients with sickle cell disease or other anemias who suffer from iron overload caused by regular blood transfusions.

Phase:

Phase 4

Details

Lead Sponsor:

ApoPharma

Treatments:

Deferiprone
Iron